FDA Panel in Favor of TriClip for Tricuspid Regurgitation

An FDA advisory panel voted 13 to 1 that the benefits of Abbott's first-of-its-kind transcatheter system to treat tricuspid regurgitation outweigh any potential risks.

Related Keywords

Nevada ,United States ,New Mexico ,Minneapolis ,Minnesota ,Canada ,University Of Nevada ,University Of South Carolina ,South Carolina ,University Of New Mexico ,Reno ,Charleston ,Albuquerque ,America ,Marc Katz ,James Blankenship ,Abbott Triclip ,Paul Hauptman ,Bradley Bart ,American College Of Cardiology World Congress ,Division Of Cardiology ,Minneapolis Va Medical Center ,Reno School Of Medicine ,Drug Administration ,Division Of Cardiothoracic Surgery ,Circulatory System Devices Panel ,Medical Devices Advisory Committee ,North America ,Medscape Cardiology ,American College ,World Congress ,New England Journal ,Reno School ,Cardiothoracic Surgery ,Medical University ,Cardiac Surgeries ,Cardiac Surgery ,Tricuspid Regurgitation ,Tricuspid Insufficiency ,Heart Failure ,Cardio Thoracic Surgery ,Heart ,Surgery ,Arthroplasty ,Total Hip Arthroplasty ,Ha Total Hip Arthroplasty ,Total Hip Replacement ,Europe ,European ,Hip Replacement ,Mitral Valve ,Thumb ,Quality Of Life ,Pol ,